Evidence map›Paper›PMID 36991155›Full record

ArticleJournal of gastroenterology2023

Serum osteopontin predicts the response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.

Reika Yamauchi, Takanori Ito, Sachiyo Yoshio, Takafumi Yamamoto, Kazuyuki Mizuno, Masatoshi Ishigami, Hiroki Kawashima, Satoshi Yasuda, Shigeo Shimose, Hideki Iwamoto and 6 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Journal of gastroenterology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024
    Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 1 country.

Reika Yamauchi *Department of Liver Diseases, The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, 1-7-1, Kohnodai, Ichikawa, 272-8516, Japan.
Takanori Ito *Division of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Sachiyo YoshioDepartment of Liver Diseases, The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, 1-7-1, Kohnodai, Ichikawa, 272-8516, Japan. sachiyo@hospk.ncgm.go.jp.ORCID 0000-0001-7860-6916
Takafumi YamamotoDivision of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Kazuyuki MizunoDivision of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Masatoshi IshigamiDivision of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Hiroki KawashimaDivision of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Satoshi YasudaDepartment of Gastroenterology, Ogaki Municipal Hospital, Ogaki, Japan.
Shigeo ShimoseDivision of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan.
Hideki IwamotoDivision of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan.
Taiji YamazoeDepartment of Liver Diseases, The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, 1-7-1, Kohnodai, Ichikawa, 272-8516, Japan.
Taizo MoriDepartment of Liver Diseases, The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, 1-7-1, Kohnodai, Ichikawa, 272-8516, Japan.
Eiji KakazuDepartment of Liver Diseases, The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, 1-7-1, Kohnodai, Ichikawa, 272-8516, Japan.
Takumi KawaguchiDivision of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan.
Hidenori ToyodaDepartment of Gastroenterology, Ogaki Municipal Hospital, Ogaki, Japan.
Tatsuya KantoDepartment of Liver Diseases, The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, 1-7-1, Kohnodai, Ichikawa, 272-8516, Japan.
National Center for Global Health and Medicine · JPNagoya University · JPKurume University · JPOgaki Municipal Hospital · JP

Funding

AMED 22fk0210094AMED 22fk0210110Grants-in-Aid for Scientific Research 21K08020
6 · The paper itself

Abstract

backgroundCombination therapy with anti-programmed death-ligand 1 and anti-vascular endothelial growth factor (VEGF) antibodies has become the standard treatment for un-resectable hepatocellular carcinoma (uHCC). We aimed to identify predictive circulating biomarkers for the outcome/response of the combination therapy in uHCC patients.

methodsThis prospective multicenter study enrolled 70 patients with uHCC who received atezolizumab and bevacizumab (Atez/Bev). We evaluated 47 circulating proteins in sera before and after 1 and 6 weeks of Atez/Bev therapy by multiplex bead-based immunoassay and ELISA. As controls, we analyzed the sera from 62 uHCC patients before treatment of lenvatinib (LEN) and healthy volunteers (HVs).

resultsThe disease control rate was 77.1%. Median progression-free survival (PFS) was 5.7 months (95% confidence interval [CI] = 3.8-9.5). The pretreatment levels of osteopontin (OPN), angiopoietin-2, VEGF, S100-calcium-binding protein A8/S100-calcium-binding protein A9, soluble programmed cell death-1, soluble CD163, and 14 cytokines/chemokines were higher in patients with uHCC than in HVs. Among these, pretreatment OPN levels were higher in PD group than in non-PD group for Atez/Bev. The PD rate was higher in high OPN group than in low OPN group. Multivariate analysis identified high pretreatment OPN and high α-fetoprotein levels as independent predictors of PD. In the sub-analysis of Child-Pugh class A patients, PFS was also shorter in the high OPN group than in the low OPN group. Pretreatment OPN level was not associated with treatment response for LEN.

conclusionHigh serum OPN levels were associated with poor response to Atez/Bev in patients with uHCC.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsAntibodies, Monoclonal, HumanizedBevacizumabCalcium-Binding ProteinsHumansOsteopontinProspective StudiesVascular Endothelial Growth Factor AAntibodies, Monoclonal, HumanizedatezolizumabBevacizumabCalcium-Binding ProteinsOsteopontinVascular Endothelial Growth Factor AAngiopoietin-2Immune checkpoint inhibitorMacrophagePD-L1VEGF

Identifiers

PMID36991155
OpenAlexW4361280808

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.